Success Metrics

Clinical Success Rate
96.6%

Based on 28 completed trials

Completion Rate
97%(28/29)
Active Trials
0(0%)
Results Posted
29%(8 trials)
Terminated
1(3%)

Phase Distribution

Ph phase_2
1
3%
Ph phase_1
2
6%
Ph phase_4
13
38%
Ph phase_3
14
41%

Phase Distribution

2

Early Stage

1

Mid Stage

27

Late Stage

Phase Distribution30 total trials
Phase 1Safety & dosage
2(6.7%)
Phase 2Efficacy & side effects
1(3.3%)
Phase 3Large-scale testing
14(46.7%)
Phase 4Post-market surveillance
13(43.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.3%

28 of 31 finished

Non-Completion Rate

9.7%

3 ended early

Currently Active

0

trials recruiting

Total Trials

34

all time

Status Distribution
Completed(28)
Terminated(3)
Other(3)

Detailed Status

Completed28
unknown3
Withdrawn2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
34
Active
0
Success Rate
96.6%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (6.7%)
Phase 21 (3.3%)
Phase 314 (46.7%)
Phase 413 (43.3%)

Trials by Status

terminated13%
withdrawn26%
completed2882%
unknown39%

Recent Activity

Clinical Trials (34)

Showing 20 of 34 trialsScroll for more
NCT01051531Phase 3

A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With Schizophrenia

Completed
NCT01527305Phase 4

A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia

Completed
NCT01451736Phase 4

Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia

Completed
NCT04572685Phase 1

Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients

Completed
NCT02146547Phase 4

European Long-acting Antipsychotics in Schizophrenia Trial

Completed
NCT03345979Phase 3

A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia

Completed
NCT04064476

The Effect of Long-acting Antipsychotics on Schizophrenia Patients With Violence Risk

Unknown
NCT02600741

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

Completed
NCT03390712

Mirror-image Study of Paliperidone Palmitate and Risperidone Long-acting Injection

Unknown
NCT03080194Phase 4

The Effect of a Community-based LAI-treated Management Model on the Violence Risk of Patients With Schizophrenia

Unknown
NCT01136772Phase 4

A Comparison of Long-acting Injectable Medications for Schizophrenia

Completed
NCT01947803Phase 4

A Safety and Effectiveness Study of Paliperidone Palmitate in Chinese Patients With Schizophrenia

Completed
NCT01362426

Paliperidone Palmitate Effectiveness Assessment Registry - Longitudinal (PEARL)

Completed
NCT01685931Phase 4

A Study of Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics

Completed
NCT01860781Phase 4

The Effect of Paliperidone Palmitate in Schizophrenia

Completed
NCT01157351Phase 4

15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated

Completed
NCT01193153Phase 3

A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder

Completed
NCT01211704Phase 4

Paliperidone Palmitate Efficacy and Safety in Bipolar Disorder Complicated by Alcoholism

Withdrawn
NCT01448720Phase 3

Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate

Completed
NCT01682161Phase 4

A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone Palmitate

Completed

Drug Details

Intervention Type
DRUG
Total Trials
34